PAVM - PAVmed Inc Stock Price, Fair Value and News

1.86USD-0.01 (-0.53%)Market Closed

Market Summary

USD1.86-0.01

Market Closed

-0.53%

PAVM Stock Price

View Fullscreen

PAVM RSI Chart

PAVM Valuation

Market Cap

17.2M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

EV/EBITDA

0.03

Price/Free Cashflow

-0.33

PAVM Price/Sales (Trailing)

PAVM Profitability

Operating Margin

-161.85%

EBT Margin

-3232.61%

Return on Equity

267.2%

Return on Assets

-193.77%

Free Cashflow Yield

-304.79%

PAVM Fundamentals

PAVM Revenue

Revenue (TTM)

2.5M

Rev. Growth (Yr)

836.61%

Rev. Growth (Qtr)

32.62%

PAVM Earnings

Earnings (TTM)

-64.2M

Earnings Growth (Yr)

31.4%

Earnings Growth (Qtr)

20.57%

Breaking Down PAVM Revenue

Last 30 days

-13.8%

Last 90 days

-19.7%

Trailing 12 Months

279.9%

How does PAVM drawdown profile look like?

PAVM Financial Health

Current Ratio

0.45

PAVM Investor Care

Shares Dilution (1Y)

36.77%

Diluted EPS (TTM)

-9.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	634.0K	800.0K	1.5M	2.5M
2022	469.3K	438.5K	407.8K	377.0K
2021	0	0	0	500.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of PAVmed Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 22, 2024	baxter timothy e	acquired	-	-	65,000	-
Feb 22, 2024	sparks ronald m	acquired	-	-	65,000	-
Feb 22, 2024	glennon michael j	acquired	-	-	65,000	-
Feb 22, 2024	cox james l	acquired	-	-	65,000	-
Feb 22, 2024	white debra	acquired	-	-	65,000	-
Feb 22, 2024	harvey joan b	acquired	-	-	65,000	-
Dec 07, 2022	glennon michael j	bought	62,320	0.6232	100,000	-
Dec 06, 2022	glennon michael j	bought	56,082	0.6373	88,000	-
Dec 05, 2022	glennon michael j	bought	42,606	0.6872	62,000	-
May 04, 2022	o'neil shaun	sold (taxes)	-35,790	1.38	-25,935	chief operating officer

Which funds bought or sold PAVM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	Valeo Financial Advisors, LLC	unchanged	-	-41,835	45,216	-%
Apr 15, 2024	THOMPSON INVESTMENT MANAGEMENT, INC.	unchanged	-	-7.00	9.00	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-9,000	10,000	-%
Apr 02, 2024	M&R CAPITAL MANAGEMENT INC	unchanged	-	-133	143	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-589	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-120	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	1,246,740	1,246,740	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-1,121,420	-	-%
Feb 27, 2024	LAZARI CAPITAL MANAGEMENT, INC.	sold off	-100	-26,219	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-11,370	-	-%

Are Funds Buying or Selling PAVM?

Are funds buying PAVM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PAVM

No. of Funds

Unveiling PAVmed Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ayrton capital llc	9.9%	851,018	SC 13G
Jul 08, 2022	blackrock inc.	1.6%	1,440,200	SC 13G
Feb 04, 2022	blackrock inc.	5.4%	4,786,168	SC 13G
Oct 06, 2021	sirovich matthew	2.9%	2,504,244	SC 13G/A
Jan 26, 2021	sirovich matthew	8.4%	5,539,750	SC 13G/A
Feb 14, 2020	sirovich matthew	14.4%	5,926,910	SC 13G/A

Recent SEC filings of PAVmed Inc

View All Filings

Date Filed	Form Type	Document
Mar 25, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	8-K	Current Report
Mar 08, 2024	8-K	Current Report
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to PAVmed Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-2.36%	-14.10%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.62	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

PAVmed Inc News

Latest updates

PAVmed Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	32.6%	1,049,000	791,000	166,000	446,000	112,000	76,000	-	189,000	194,500	200,000
Cost Of Revenue	-9.5%	1,610,500	1,779,000	1,685,000	1,346,000	1,618,500	1,626,000	-	369,000	-	144,000
Gross Profit	-	-	-	-	-	-	-	-	-180,000	-	56,000
Costs and Expenses	6.8%	17,431,500	16,319,000	16,650,000	20,847,000	24,713,000	23,443,000	23,484,000	19,824,000	-	13,868,000
Operating Expenses	-	-	-	-	-	-	-	23,477,000	19,280,000	19,537,500	13,724,000
S&GA Expenses	16.8%	4,689,500	4,016,000	4,339,000	4,539,000	5,759,000	4,736,000	4,898,000	3,925,000	3,340,000	2,293,000
R&D Expenses	7.6%	3,401,000	3,161,000	3,469,000	4,439,000	6,569,000	6,202,000	6,740,000	5,932,000	6,969,000	5,305,000
EBITDA Margin	43.5%	-30.89	-54.64	-113	-160	-263	-233	-183	-138	-111	-
Interest Expenses	-88.1%	19,000	159,000	228,000	183,000	-	525,000	523,000	-	-	-
Earnings Before Taxes	20.0%	-17,407,500	-21,750,000	-17,892,000	-22,214,000	-24,572,000	-29,932,000	-29,101,000	-19,633,000	-19,678,500	-13,668,000
EBT Margin	43.3%	-32.33	-57.05	-118	-166	-273	-241	-187	-139	-112	-
Net Income	20.6%	-14,036,000	-17,671,000	-14,537,000	-17,931,000	-20,460,000	-26,126,000	-25,525,000	-16,872,000	-17,218,000	-12,227,000
Net Income Margin	43.8%	-26.17	-46.60	-98.82	-142	-236	-210	-163	-123	-100	-
Free Cashflow	-8.6%	-12,057,000	-11,107,000	-12,801,000	-16,313,000	-17,121,000	-19,657,000	-22,910,000	-12,837,000	-18,054,000	-8,053,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-21.2%	33.00	42.00	54.00	65.00	54.00	72.00	82.00	84.00	87.00	43.00	47.00	51.00	20.00	11.00	9.00	10.00	7.00	4.00	7.00	4.00	8.00
Current Assets	-24.5%	24.00	32.00	43.00	54.00	44.00	62.00	71.00	71.00	83.00	42.00	46.00	51.00	19.00	10.00	8.00	9.00	7.00	4.00	7.00	4.00	8.00
Cash Equivalents	-25.6%	20.00	26.00	37.00	49.00	40.00	57.00	65.00	65.00	77.00	37.00	43.00	49.00	17.00	8.00	7.00	9.00	6.00	4.00	7.00	4.00	8.00
Inventory	-	0.00	-	-	-	0.00	-	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-2.0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	0.00	-	-	0.00	-	-	-	-	0.00	0.00	0.00	0.00
Liabilities	-1.2%	57.00	58.00	55.00	54.00	43.00	44.00	41.00	20.00	8.00	8.00	5.00	3.00	20.00	25.00	22.00	26.00	12.00	7.00	9.00	10.00	11.00
Current Liabilities	-0.6%	54.00	55.00	51.00	51.00	41.00	42.00	39.00	17.00	8.00	-	-	-	-	25.00	22.00	-	12.00	-	-	-	11.00
Shareholder's Equity	-Infinity%	-24.02	-	-	11.00	11.00	29.00	41.00	65.00	79.00	35.00	42.00	48.00	2.00	-	-	-	-	-	-	-	-
Retained Earnings	-5.7%	-294	-278	-260	-246	-228	-207	-181	-155	-138	-121	-109	-97.78	-88.27	-79.46	-73.91	-68.26	-53.71	-47.40	-44.25	-40.59	-36.99
Additional Paid-In Capital	2.3%	238	232	226	221	216	214	201	200	198	154	150	145	88.00	64.00	60.00	51.00	48.00	43.00	41.00	33.00	33.00
Shares Outstanding	7.5%	9.00	8.00	7.00	7.00	6.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-
Minority Interest	8.7%	30.00	27.00	31.00	33.00	21.00	20.00	19.00	19.00	18.00	0.00	-0.91	-2.25	-2.37	-1.86	-1.48	-1.23	-0.81	-0.52	-0.34	-0.23	-0.16
Float	-	-	-	39.00	-	-	-	71.00	-	-	-	470	-	-	-	82.00	-	-	-	30.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-7.1%	-11,874	-11,089	-12,786	-16,287	-16,823	-19,341	-22,558	-12,263	-16,777	-8,018	-6,628	-9,168	-6,728	-5,840	-5,555	-3,791	-4,090	-2,878	-2,519	-3,870	-3,019
Share Based Compensation	-12.3%	1,968	2,245	2,507	4,419	4,948	4,764	5,007	4,814	4,380	3,990	5,203	1,436	586	586	529	344	394	330	388	459	329
Cashflow From Investing	-916.7%	-183	-18.00	-15.00	974	-298	-1,316	-2,552	-574	-3,377	-135	-168	-36.00	-8.00	-3.00	-42.00	-2.00	-2.00	-	-22.00	-3.00	-3.14
Cashflow From Financing	1402.3%	5,288	352	684	24,849	80.00	12,289	25,526	316	60,071	2,284	1,460	40,494	15,699	7,056	3,946	6,305	6,214	67.00	5,259	-159	2,003

PAVM Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Income Statement [Abstract]

Revenue

$ 2,452

$ 377

Operating expenses:

Cost of revenue

6,420

3,614

Sales and marketing

17,583

19,318

General and administrative

30,947

41,410

Amortization of acquired intangible assets

2,021

1,784

Research and development

14,276

25,338

Total operating expenses

71,247

91,464

Operating loss

(68,795)

(91,087)

Other income (expense):

Interest income

505

169

Interest expense

(589)

(1,281)

Change in fair value - Senior Secured Convertible Notes

(6,026)

(1,273)

Loss on issue and offering costs - Senior Secured Convertible Note

(1,186)

(4,332)

Debt extinguishments loss - Senior Secured Convertible Notes

(3,782)

(5,434)

Change in fair value - derivative liability

(390)

Gain on sale of intellectual property

1,000

Other income (expense), net

(10,468)

(12,151)

Loss before provision for income tax

(79,263)

(103,238)

Provision for income taxes

Net loss before noncontrolling interests

(79,263)

(103,238)

Net loss attributable to the noncontrolling interests

15,088

14,255

Net loss attributable to PAVmed Inc.

(64,175)

(88,983)

Less: Deemed dividend on Series Z warrant modification

(1,791)

Less: Series B Convertible Preferred Stock dividends earned

(304)

(281)

Net loss attributable to PAVmed Inc. common stockholders

$ (66,270)

$ (89,264)

Per share information(1):

Net loss per share attributable to PAVmed Inc. common stockholders - basic

^[1],[2]

$ (9.16)

$ (15.03)

Net loss per share attributable to PAVmed Inc. common stockholders - diluted

^[1],[2]

$ (9.16)

$ (15.03)

Weighted average common shares outstanding, basic

^[2]

7,231,546

5,938,406

Weighted average common shares outstanding, diluted

^[2]

7,231,546

5,938,406

[1]	- Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.
[2]	Reflects the Company’s 1-for-15 reverse stock split that became effective December 7, 2023. Refer to Note 3 - Summary of Significant Accounting Policies for further information.

PAVM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 19,639	$ 39,744
Accounts receivable	61	17
Inventory	278	111
Prepaid expenses, deposits, and other current assets	4,520	4,054
Total current assets	24,498	43,926
Fixed assets, net	1,783	2,451
Operating lease right-of-use assets	4,267	3,037
Intangible assets, net	1,424	3,445
Other assets	1,147	1,121
Total assets	33,119	53,980
Current liabilities:
Accounts payable	1,786	2,704
Accrued expenses and other current liabilities	6,626	3,705
Operating lease liabilities, current portion	1,565	1,141
Senior Secured Convertible Notes - at fair value	44,200	33,650
Total current liabilities	54,177	41,200
Operating lease liabilities, less current portion	2,960	1,846
Total liabilities	57,137	43,046
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,305,213 at December 31, 2023 and 1,205,759 shares at December 31, 2022	2,993	2,695
Common stock, $0.001 par value. Authorized, 50,000,000 shares; 8,578,505 and 6,300,703 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	9	6
Additional paid-in capital	237,600	216,195
Accumulated deficit	(294,433)	(228,169)
Treasury stock		(408)
Total PAVmed Inc. Stockholders’ Equity (Deficit)	(53,831)	(9,681)
Noncontrolling interests	29,813	20,615
Total Stockholders’ Equity (Deficit)	(24,018)	10,934
Total Liabilities and Stockholders’ Equity (Deficit)	$ 33,119	$ 53,980

About PAVmed Inc

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

CEO	Dr. Lishan Aklog M.D.
WEBSITE	pavmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	124

PAVmed Inc Frequently Asked Questions

What is the ticker symbol for PAVmed Inc? What does PAVM stand for in stocks?

PAVM is the stock ticker symbol of PAVmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PAVmed Inc (PAVM)?

As of Tue Apr 23 2024, market cap of PAVmed Inc is 17.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PAVM stock?

You can check PAVM's fair value in chart for subscribers.

What is the fair value of PAVM stock?

You can check PAVM's fair value in chart for subscribers. The fair value of PAVmed Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PAVmed Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PAVM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PAVmed Inc a good stock to buy?

The fair value guage provides a quick view whether PAVM is over valued or under valued. Whether PAVmed Inc is cheap or expensive depends on the assumptions which impact PAVmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PAVM.

What is PAVmed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, PAVM's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PAVM PE ratio will change depending on the future growth rate expectations of investors.